De-escalation of immunomodulator and biological therapy in inflammatory bowel disease

Peyrin-Biroulet, 2015, Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target, Am J Gastroenterol, 110, 1324, 10.1038/ajg.2015.233 Colombel, 2017, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet, 390, 2779, 10.1016/S0140-6736(17)32641-7 Khanna, 2015, Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial, Lancet, 386, 1825, 10.1016/S0140-6736(15)00068-9 Bemelman, 2018, ECCO guideline/consensus paper ECCO-ESCP consensus on surgery for Crohn's disease, J Crohns Colitis, 12, 1 Van Der Woude, 2015, ECCO guidelines/consensus paper the second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J Crohns Colitis, 9, 107, 10.1093/ecco-jcc/jju006 Gomollón, 2017, 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management, J Crohns Colitis, 11, 03, 10.1093/ecco-jcc/jjw168 Harbord, 2017, Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management, J Crohns Colitis, 11, 769, 10.1093/ecco-jcc/jjx009 Torres, 2017, Crohn's disease, Lancet, 389, 1741, 10.1016/S0140-6736(16)31711-1 Beaugerie, 2019, Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol, 17, 370, 10.1016/j.cgh.2018.07.013 Lemaitre, 2017, Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease, JAMA, 318, 1679, 10.1001/jama.2017.16071 Kirchgesner, 2018, Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases, Gastroenterology, 155, 337, 10.1053/j.gastro.2018.04.012 Beaugerie, 2009, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, 374, 1617, 10.1016/S0140-6736(09)61302-7 van der Valk, 2014, Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study, Gut, 63, 72, 10.1136/gutjnl-2012-303376 Vande Casteele, 2015, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease, Gastroenterology, 148, 1320, 10.1053/j.gastro.2015.02.031 Attar, 2019, Cost savings using a test-based de-escalation strategy for patientswith Crohn's disease in remission on optimized infliximab: a discrete event model study, Dig Liver Dis, 51, 112, 10.1016/j.dld.2018.08.029 Wenzl, 2015, Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease, Dig Dis Sci, 60, 1414, 10.1007/s10620-014-3419-5 Lémann, 2005, A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine, Gastroenterology, 128, 1812, 10.1053/j.gastro.2005.03.031 Vilien, 2004, Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year, Aliment Pharmacol Ther, 19, 1147, 10.1111/j.1365-2036.2004.01944.x Hawthorne, 1992, Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, BMJ, 305, 20, 10.1136/bmj.305.6844.20 O'Donoghue, 1978, Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease, Lancet, 2, 955, 10.1016/S0140-6736(78)92524-2 Roblin, 2017, Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial, Aliment Pharmacol Ther, 46, 142, 10.1111/apt.14106 Fischer, 2017, Risk factors for rescue therapy in Crohn's patients maintained on infliximab after withdrawal of the immunomodulator: a long-term follow-up, Dig Dis Sci, 62, 3131, 10.1007/s10620-017-4771-z Kierkuś, 2015, Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease, J Pediatr Gastroenterol Nutr, 60, 580, 10.1097/MPG.0000000000000684 Filippi, 2015, Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience, J Crohns Colitis, 9, 252, 10.1093/ecco-jcc/jjv001 Drobne, 2015, Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease, Clin Gastroenterol Hepatol, 13, 514, 10.1016/j.cgh.2014.07.027 Choi, 2010, Withdrawal of azathioprine in luminal Crohn's disease treated with infliximab maintenance therapy: a retrospective case-control study (abstr), J Gastroenterol Hepatol, 25, A86 Oussalah, 2010, Predictors of infliximab failure after azathioprine withdrawal in crohn's disease treated with combination therapy, Am J Gastroenterol, 105, 1142, 10.1038/ajg.2010.158 Sokol, 2009, Withdrawal of immunosuppression in inflammatory bowel disease treated with infliximab maintenance therapy, Gastroenterology, 136, A187, 10.1016/S0016-5085(09)60844-1 Van Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004 Torres, 2015, Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease, Gastroenterology, 149, 1716, 10.1053/j.gastro.2015.08.055 Treton, 2009, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol, 7, 80, 10.1016/j.cgh.2008.08.028 Boyapati, 2018, Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn' s disease, Cochrane Database Syst Rev, 12 Fraser, 2002, The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 693, 10.1046/j.1365-2036.2002.01227.x Hisamatsu, 2019 Kennedy, 2019, Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study, Lancet Gastroenterol Hepatol, 4, 341, 10.1016/S2468-1253(19)30012-3 Vermeire, 2018, Immunogenicity of biologics in inflammatory bowel disease, Therap Adv Gastroenterol, 11, 1, 10.1177/1756283X17750355 Nanda, 2013, Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis, Am J Gastroenterol, 108, 40, 10.1038/ajg.2012.363 Karmiris, 2009, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, Gastroenterology, 137, 1628, 10.1053/j.gastro.2009.07.062 Yarur, 2015, Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy, Clin Gastroenterol Hepatol, 13, 1118, 10.1016/j.cgh.2014.12.026 Ungar, 2014, The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut, 63, 1258, 10.1136/gutjnl-2013-305259 Drobne, 2019, Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease, Aliment Pharmacol Ther, 49, 880, 10.1111/apt.15179 Lega, 2019, Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD proactively optimized infliximab monotherapy is as effective as combination therapy in IBD, Inflamm Bowel Dis, 1, 134, 10.1093/ibd/izy203 Steenholdt, 2012, Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study, Scand J Gastroenterol, 47, 518, 10.3109/00365521.2012.660541 Molander, 2014, Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission, Inflamm Bowel Dis, 20, 1021 Sorrentino, 2014, Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?, Inflamm Bowel Dis, 20, 757, 10.1097/01.MIB.0000442680.47427.bf Kennedy, 2016, Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis, Aliment Pharmacol Ther, 43, 910, 10.1111/apt.13547 Papamichael, 2015, Withdrawal of anti-tumour alfa necrosis factor therapy in inflammatory bowel disease, World J Gastroenterol, 21, 4773, 10.3748/wjg.v21.i16.4773 Frias Gomes, 2018, De-escalation of therapy in inflammatory bowel disease, Curr Gastroenterol Rep, 20, 35, 10.1007/s11894-018-0643-8 Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, 142, 63, 10.1053/j.gastro.2011.09.034 Reenaers, 2018, Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission, Clin Gastroenterol Hepatol, 16, 234, 10.1016/j.cgh.2017.09.061 Casanova, 2017, Evolution after Anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study, Am J Gastroenterol, 112, 120, 10.1038/ajg.2016.569 Papamichael, 2015, Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission, Clin Gastroenterol Hepatol, 13, 1103, 10.1016/j.cgh.2014.11.026 Dai, 2014, Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy, PLoS One, 9, 1, 10.1371/journal.pone.0110797 Farkas, 2014, Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy, World J Gastroenterol, 20, 2995, 10.3748/wjg.v20.i11.2995 Chauvin, 2014, Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: a retrospective study, Dig Liver Dis, 46, 695, 10.1016/j.dld.2014.04.012 Molnár, 2013, Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy, Aliment Pharmacol Ther, 37, 225, 10.1111/apt.12160 Gisbert, 2016, The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 111, 632, 10.1038/ajg.2016.54 Fiorino, 2016, Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study, Clin Gastroenterol Hepatol, 14, 1426, 10.1016/j.cgh.2016.05.044 Kotlyar, 2011, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease, Clin Gastroenter, 9, 36, 10.1016/j.cgh.2010.09.016 Doherty, 2018, European Crohn's and Colitis Organisation topical review on treatment withdrawal (exit strategies) in inflammatory bowel disease, J Crohns Colitis, 5, 17, 10.1093/ecco-jcc/jjx101 Molnar, 2008, Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?, J Crohns Colitis, 2, 322, 10.1016/j.crohns.2008.07.003 Domènech, 2005, Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?, Aliment Pharmacol Ther, 22, 1107, 10.1111/j.1365-2036.2005.02670.x Mooiweer, 2015, Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission, J Crohns Colitis, 9, 50, 10.1093/ecco-jcc/jju003 Kennedy, 2014, Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients, Aliment Pharmacol Ther, 40, 1313, 10.1111/apt.12980 Zenlea, 2016, Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study, Am J Gastroenterol, 111, 685, 10.1038/ajg.2016.50 Echarri, 2013, Predictors of relapse after discontinuing anti-TNF therapy in Crohn's disease patients on deep remission, J Crohns Colitis, 7, S171, 10.1016/S1873-9946(13)60424-9 Bortlik, 2016, Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation, Scand J Gastroenterol, 51, 196, 10.3109/00365521.2015.1079924 Rajca, 2014, Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease, Inflamm Bowel Dis, 20, 978 Lennard, 1985, Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells, Br J Dermatol, 113, 723, 10.1111/j.1365-2133.1985.tb02408.x Na, 2016, Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia, Br J Haematol, 174, 550, 10.1111/bjh.14083 Jani, 2018, The association of biologic drug-levels with infection risk: results from the British Society for Rheumatology biologics register for rheumatoid arthritis, Ann Rheum Dis, 77, 163 Petitcollin, 2019, Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases, Clin Pharmacol Ther, 106, 605, 10.1002/cpt.1429 Lucidarme, 2019, Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring, Aliment Pharmacol Ther, 49, 147, 10.1111/apt.15046 Van Steenbergen, 2017, Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease—a nested case-control study, Aliment Pharmacol Ther, 45, 923, 10.1111/apt.13964 Baert, 2013, Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients, J Crohns Colitis, 7, 154, 10.1016/j.crohns.2012.03.018 Schreiber, 2012, Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey, BMC Gastroenterol, 15, 108, 10.1186/1471-230X-12-108 De Suray, 2012, P274 Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub-analysis of the STORI study, J Crohns Colitis, 6, S118, 10.1016/S1873-9946(12)60294-3 Molander, 2015, Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?, J Crohns Colitis, 9, 33 Monterubbianesi, 2015, P529. Maintenance of clinical remission in Crohn's disease patients after discontinuation of antiTNF agents: results from a single centre cohort, J Crohns Colitis, 9, S345, 10.1093/ecco-jcc/jju027.647 Brooks, 2014, Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission, J Crohns Colitis, 11, 1456 Molander, 2017, Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents, Scand J Gastroenterol, 52, 284, 10.1080/00365521.2016.1250942 Baert, 2014, Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy, Clin Gastroenterol Hepatol, 12, 1474, 10.1016/j.cgh.2014.01.033 Vermeire, 2017, Long-term efficacy of vedolizumab for Crohn's disease, J Crohns Colitis, 11, 412 Louis, 2018, Stopping biologics in IBD—what is the evidence?, Inflamm Bowel Dis, 24, 725, 10.1093/ibd/izx098 Papamichael, 2015, Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission, Clin Gastroenterol Hepatol, 13, 1103, 10.1016/j.cgh.2014.11.026 Siegel, 2017 Siegel, 2018 Buhl, 2014, Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial, BMJ Open, 4, 1, 10.1136/bmjopen-2014-005887 Lee, 2017, Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease, Nat Genet, 49, 262, 10.1038/ng.3755 Lee, 2011, Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis, J Clin Invest, 121, 4170, 10.1172/JCI59255 West, 2017, Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease, Nat Med, 23, 579, 10.1038/nm.4307 Gobbi, 2018, Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases, Biol Ther, 12, 37 Bartelds, 2009, Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms, Arthritis Rheum, 60, 2541, 10.1002/art.24709 Sazonovs, 2018, HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy, bioRxiv de Jong, 2017, Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial, Lancet, 390, 959, 10.1016/S0140-6736(17)31327-2 White, 2018, Novel oral-targeted therapies in inflammatory bowel disease, Aliment Pharmacol Ther, 47, 1610, 10.1111/apt.14669 Panés, 2018